Director/PDMR Shareholding

September 6, 2021
RNS Number : 8886K
Renalytix PLC
06 September 2021

Renalytix plc

("Renalytix" or the "Company") 


Director/PDMR Dealing


New York, 6 September 2021 - Renalytix (LSE: RENX) announces that it has been advised of the sale by O. James Sterling, the Company's Chief Financial Officer, of 3,000 American Depositary Shares ("ADS"), each representing two ordinary shares of £0.0025 each in the capital of the Company ("Ordinary Shares"), under a Rule 10b5-1 trading plan established in accordance with Rule 10b5-1 under the U.S. Securities Exchange Act of 1934, as amended, and the EU Market Abuse Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").


Rule 10b5-1 plans permit directors, officers and other company insiders to adopt, at times when they are not in possession of material, non-public information, or inside information, written plans for trading securities in a non-discretionary, pre-scheduled manner in the future.


Following completion of the sale, O. James Sterling is interested in 1,805,236 Ordinary Shares representing 2.50% of the current issued share capital of the Company.


For further information, please contact: 


Renalytix plc 

James McCullough, CEO  

Via Walbrook PR  

Stifel (Nominated Adviser, Joint Broker) 

Tel: 020 7710 7600 

Alex PriceNicholas Moore  

Investec Bank plc (Joint Broker) 

Tel: 020 7597 4000 

Gary Clarence / Daniel Adams 

Walbrook PR Limited 

Tel: 020 7933 8780 or 

Paul McManus / Lianne Cawthorne 

Mob: 07980 541 893 / 07584 391 303 


About Kidney Disease 

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally.  The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD).  Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage.  Each year kidney disease kills more people than breast and prostate cancer.  Every day, 13 patients in the United States die while waiting for a kidney transplant.




About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit

The information contained in this notification is disclosed in accordance with the requirements of MAR.



Details of the person discharging managerial responsibilities/person closely associated




O. James Sterling



Reason for the notification




Chief Financial Officer




Initial notification /Amendment


Initial Notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




Renalytix plc



Legal Entity Identifier




Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


Description of the financial instrument, type of instrument


Identification code

ADS', each ADS representing two Ordinary Shares of £0.0025 each.






Nature of the transaction

Sale of ADS' under a 10b5-1 trading plan





US Dollar


Price(s) and volume(s)







3,000 ADS (representing 6,000 Ordinary Shares)




Aggregated information

- Aggregated volume

- Price

- Aggregated total



3,000 ADS (representing 6,000 Ordinary Shares)




Date of the transaction

31 August 2021



Place of the transaction

Nasdaq Stock Exchange






This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.